PEPCID TAB 20MG TABLET

Држава: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

FAMOTIDINE

Доступно од:

MERCK CANADA INC

АТЦ код:

A02BA03

INN (Међународно име):

FAMOTIDINE

Дозирање:

20MG

Фармацеутски облик:

TABLET

Састав:

FAMOTIDINE 20MG

Пут администрације:

ORAL

Јединице у пакету:

28

Тип рецептора:

Prescription

Терапеутска област:

HISTAMINE H2-ANTAGONISTS

Резиме производа:

Active ingredient group (AIG) number: 0118722001; AHFS:

Статус ауторизације:

CANCELLED POST MARKET

Датум одобрења:

2013-07-15

Карактеристике производа

PRODUCT MONOGRAPH
PEPCID
®
Tablets
(famotidine tablets, USP)
20, 40 mg
Histamine H
2
Receptor Antagonist
MERCK CANADA INC.
16750 route Transcanadienne
Kirkland QC H9H 4M7
Canada
http//www.merck.ca
Date of Revision:
April 27, 2011
SUBMISSION CONTROL NUMBER. 145448
®
Registered trademark of Merck Sharp & Dohme Corp., a subsidiary of
MERCK & CO., INC. Used under license.
_© 2011, Merck Canada Inc., a subsidiary OF MERCK & CO., INC. All
rights reserved. _
_ _
1
PRODUCT MONOGRAPH
NAME OF DRUG
PEPCID
®
Tablets
(famotidine tablets, USP)
20, 40 mg
THERAPEUTIC CLASSIFICATION
Histamine H
2
Receptor Antagonist
CLINICAL PHARMACOLOGY
PEPCID
®
(famotidine) is a competitive inhibitor of histamine H
2
-receptors. The
primary clinically important pharmacologic activity of PEPCID
®
is inhibition of
gastric juice secretion. PEPCID
®
reduces the acid and pepsin content, as well as
the volume, of basal, nocturnal, and stimulated gastric secretion.
INDICATIONS AND CLINICAL USE
PEPCID
®
(famotidine) is indicated in the treatment of the following conditions
where a controlled reduction of gastric secretion is required:
1.
Treatment of acute duodenal ulcer;
2.
Prophylactic use in duodenal ulcer;
3.
Treatment of acute benign gastric ulcer;
4.
Treatment of pathological hypersecretory conditions (e.g.,
Zollinger-Ellison
Syndrome);
5.
Treatment of gastroesophageal reflux disease (GERD);
6.
Maintenance of remission of patients with GERD.
CONTRAINDICATIONS
Hypersensitivity to any component of this medication. Cross
sensitivity in this
class of compounds has been observed. Therefore, PEPCID
®
(famotidine)
should not be administered to patients with a history of
hypersensitivity to other
2
H
2
-receptor antagonists.
PRECAUTIONS
PATIENTS WITH MODERATE OR SEVERE RENAL INSUFFICIENCY
Since CNS adverse effects have been reported in patients with moderate
and
severe renal insufficiency, longer intervals between doses or lower
doses may
need to be used in patients with moderate (creatinine clearance 30 -
50 mL/min)
or severe (creatinine cleara